发现AD258作为具有强烈抗代活性的西格玛受体连接体
Maria Dichiara1, Francesca Alessandra Ambrosio2, Sang Min Lee3
1Dipartimento di Scienze del Farmaco e della Salute, Università degli Studi di Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
Journal of medicinal chemistry
|August 3, 2023
概括
研究人员开发了新的西格玛受体 (SR) 连接体来缓解疼痛. 化合物9d (AD258) 在没有运动障碍的临床前模型中显示出高亲和力,低毒性和强大的止痛作用.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 西格玛受体 (SRs) 与疼痛通路有关.
- 为SRs开发选择性配体是新型止痛药的关键策略.
研究的目的:
- 设计和合成新的2,7-diazaspiro[4.4]nonane衍生物作为潜在的西格玛受体连接体.
- 评估它们的结合亲和力,体外毒性和体内止痛性质.
主要方法:
- 合成 2,7-diazaspiro [4.4] 的非衍生物.
- 在西格玛-1受体 (S1R) 和西格玛-2受体 (S2R) 的结合亲和度的测量.
- 在体外毒性测定和体内止痛查,使用素诱导的全力学模型.
主要成果:
- 化合物9d (AD258) 对S1R (Ki = 3.5 nM) 和S2R (Ki = 2.6 nM) 具有很高的亲和力,在体外有毒性可以忽略不计.
- 化合物9d在低剂量 (0.6-1.25 mg/kg) 的体内表现出强烈的抗氨酸作用,并且需要S1R对抗.
- 没有观察到运动障碍,而化合物9d显示出有利的药理动力学特征.
结论:
- 化合物9d (AD258) 是一个有前途的新型止痛药候选者,向西格玛受体.
- 它的有效性与S1R对抗性有关,具有良好的安全性和药理动力学特征.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
924
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
924
Structure-Activity Relationships and Drug Design
770
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
770
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
888
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
888


